Products
Online Inquiry
R1530
Cat. No.:
0225LY-1245
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
R1530 functions as a multikinase inhibitor with dual activities in antiangiogenesis and antineoplastic therapy.
Synonym:
R-1530; R 1530; 882531-87-5; 5-(2-Chlorophenyl)-7-fluoro-1,2-dihydro-8-methoxy-3-methylpyrazolo(3,4-b)(1,4)benzodiazepine; CID 11610113; 5-(2-chlorophenyl)-7-fluoro-8-methoxy-3-methyl-1,2-dihydropyrazolo[3,4-b][1,4]benzodiazepine; 5-(2-chlorophenyl)-7-fluoro-8-methoxy-3-methyl-2,10-dihydropyrazolo[3,4-b][1,4]benzodiazepine
CAS No.:
882531-87-5
Compound CID:
135398512
Formula:
C18H14ClFN4
Formula Weight:
356.78
Specification
Targets&IC50:
VGFR2: 10 nM; FGFR1: 28 nM
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
R1530 can be used in cancer biology to investigate the multi-target inhibition of mitosis and angiogenesis.
Library Information
Target:
FLT; VEGFR; FGFR; PDGFR
Receptor:
FGFR1; FGFR2; FLT3; PDGFR; VEGFR1; VEGFR2; VEGFR3
Pathways:
Tyrosine kinase/adaptors; Angiogenesis
Plate Number:
AOCL-17
Plate Location:
a2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5 mg/mL; 14.01 mM
